Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gritstone bio Inc GRTSQ

Healthcare Biotechnology
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage... see more

Recent & Breaking News (PINL:GRTSQ)

CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 6, 2022

Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 5, 2022

Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Opportunity for Shareholders

GlobeNewswire May 2, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 27, 2022

Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery

GlobeNewswire April 12, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 30, 2022

Gritstone Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Corporate Updates

GlobeNewswire March 10, 2022

Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at the 2022 AACR Annual Meeting

GlobeNewswire March 8, 2022

Gritstone to Participate in Cowen 42nd Annual Health Care Conference

GlobeNewswire February 24, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 8, 2022

Gritstone to Participate in Precision Oncology Panel at BIO CEO & Investor Conference

GlobeNewswire February 8, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 25, 2022

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

GlobeNewswire January 13, 2022

Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19

GlobeNewswire January 4, 2022

Gritstone Announces Presentations during Three Upcoming Investor Conferences

GlobeNewswire December 30, 2021

Gritstone Announces Changes to Its Board of Directors

GlobeNewswire December 17, 2021

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 13, 2021

Gritstone bio Added to the Nasdaq Biotechnology Index

GlobeNewswire December 13, 2021

Direxion Launches mRNA ETF (MSGR)

PR Newswire December 9, 2021

Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant

GlobeNewswire December 6, 2021